Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer

Gomez-Roman, N. , McGregor, F., Chalmers, A. J. and Plumb, J. (2016) Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer. Oncotarget, 7, 16. (doi: 10.18632/oncotarget.7998) (PMID:26967059) (PMCID:PMC5008389)

116748.pdf - Published Version
Available under License Creative Commons Attribution.



The small GTPase Rab25 has been functionally linked to tumour progression and aggressiveness in ovarian cancer and promotes invasion in three-dimensional environments. This type of migration has been shown to require the expression of the hypoxia-inducible factor 1 alpha (HIF-1α). In this report we demonstrate that Rab25 regulates HIF-1α protein expression in an oxygen independent manner in a panel of cancer cell lines. Regulation of HIF-1α protein expression by Rab25 did not require transcriptional upregulation, but was dependent on de novo protein synthesis through the Erbb2/ERK1/2 and p70S6K/mTOR pathways. Rab25 expression induced HIF-1 transcriptional activity, increased cisplatin resistance, and conferred intraperitoneal growth to the A2780 cell line in immunocompromised mice. Targeting HIF1 activity by silencing HIF-1β re-sensitised cells to cisplatin in vitro and reduced tumour formation of A2780-Rab25 expressing cells in vivo in a mouse ovarian peritoneal carcinomatosis model. Similar effects on cisplatin resistance in vitro and intraperitoneal tumourigenesis in vivo were obtained after HIF1b knockdown in the ovarian cancer cell line SKOV3, which expresses endogenous Rab25 and HIF-1α at atmospheric oxygen concentrations. Our results suggest that Rab25 tumourigenic potential and chemoresistance relies on HIF1 activity in aggressive and metastatic ovarian cancer. Targeting HIF-1 activity may potentially be effective either alone or in combination with standard chemotherapy for aggressive metastatic ovarian cancer.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Gomez-Roman, Dr Maria and Plumb, Dr Jane and Chalmers, Professor Anthony
Authors: Gomez-Roman, N., McGregor, F., Chalmers, A. J., and Plumb, J.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Oncotarget
Publisher:Imact Journals
ISSN (Online):1949-2553
Published Online:09 March 2016
Copyright Holders:Copyright © 2016 Impact Journals
First Published:First published in Oncotarget 7:16
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
415251Pharmacology of anticancer gene medicinesJames CassidyCancer Research UK (CAN-RES-UK)C973/A6705RI CANCER SCIENCES